{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:45:02Z","timestamp":1792201502840,"version":"4.4.0"},"reference-count":60,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Gastric cancer (GC) has a poor prognostic and only one in four patients will have survived by 5 years after diagnosis. These poor results are due to the fact that most patients are diagnosed in advanced stages; peritoneal metastases (PM) are especially frequent and are difficult to treat. Currently, PM are considered a terminal stage of GC with a poor survival rate and are treated with palliative systemic chemotherapy. Since the beginning of the century, the treatment of PM from different origins has evolved; cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become the treatment of choice for many malignant diseases that affect the peritoneum. CRS and HIPEC have also been used for patients with GC and PM, achieving survival results that have never been achieved when using systemic chemotherapy alone. The use of HIPEC can even prevent the development of peritoneal recurrences in patients with locally advanced GC as adjuvant therapy, can reduce the volume of peritoneal disease as neoadjuvant therapy, and can control symptoms in a palliative setting. The aim of this review is to collate the current scientific evidence regarding the treatment of PM of GC origin with surgery and intraperitoneal chemotherapy.<\/jats:p>","DOI":"10.3390\/cancers15061777","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T05:22:59Z","timestamp":1678857779000},"page":"1777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-1740","authenticated-orcid":false,"given":"Israel","family":"Manzanedo","sequence":"first","affiliation":[{"name":"Department of General and Digestive Surgery, Peritoneal Carcinomatosis Unit, Hospital of Fuenlabrada, 28943 Madrid, Spain"},{"name":"Department of Surgery, Rey Juan Carlos University (URJC), 28933 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-5112","authenticated-orcid":false,"given":"Fernando","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, Peritoneal Carcinomatosis Unit, Hospital of Fuenlabrada, 28943 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbalitz","family":"P\u00e9rez-Viejo","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, Peritoneal Carcinomatosis Unit, Hospital of Fuenlabrada, 28943 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of General and Digestive Surgery, Peritoneal Carcinomatosis Unit, Hospital of Fuenlabrada, 28943 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global Burden of 5 Major Types of Gastrointestinal Cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gamboa, A.C., and Winer, J.H. (2019). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111662"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/14737140.2019.1671189","article-title":"The use of intraperitoneal chemotherapy for gastric malignancies","volume":"19","author":"Morabito","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1245\/s10434-021-11316-z","article-title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages","volume":"29","author":"Zhang","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1245\/s10434-022-12312-7","article-title":"Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis","volume":"29","author":"Martins","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP)","volume":"26","author":"Manzanedo","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/SLA.0b013e3181b0c80e","article-title":"Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma","volume":"250","author":"Kuramoto","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u00abpersonalized\u00bb approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CMAR.S149619","article-title":"Gastric cancer: Epidemiology, prevention, classification, and treatment","volume":"10","author":"Sitarz","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.21037\/jgo-20-232","article-title":"Review of management and treatment of peritoneal metastases from gastric cancer","volume":"12","author":"Manzanedo","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/07357907.2012.654871","article-title":"Peritoneal carcinomatosis: Cytoreductive surgery and HIPEC\u2014Overview and basics","volume":"30","author":"Piso","year":"2012","journal-title":"Cancer Invest."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.3748\/wjg.v20.i14.3905","article-title":"Treatment options in patients with metastatic gastric cancer: Current status and future perspectives","volume":"20","author":"Bilici","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, andomized controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomized, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10120-012-0182-1","article-title":"Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: Retrospective analysis from a single center","volume":"16","author":"Hong","year":"2013","journal-title":"Gastric Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ejso.2016.03.016","article-title":"A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent","volume":"42","author":"Yonemura","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1272\/jnms.67.5","article-title":"It\u2019s what the surgeon doesn\u2019t see that kills the patient","volume":"67","author":"Sugarbaker","year":"2000","journal-title":"J. Nippon. Med. Sch."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, andomized, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pereira, F., Serrano, A., Manzanedo, I., P\u00e9rez-Viejo, E., Gonz\u00e1lez-Moreno, S., Gonz\u00e1lez-Bay\u00f3n, L., Arjona-S\u00e1nchez, A., Torres, J., Ramos, I., and Barrios, M.E. (2022). GECOP-MMC: Phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09572-7"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","article-title":"The 30-year experience-A meta-analysis of andomized and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer","volume":"79","author":"Desiderio","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_30","first-page":"1776","article-title":"Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study","volume":"48","author":"Yonemura","year":"2001","journal-title":"Hepatogastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4251\/wjgo.v12.i7.782","article-title":"Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer","volume":"12","author":"Xie","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials","volume":"40","author":"Coccolini","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000093778","article-title":"Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study","volume":"23","author":"Zhu","year":"2006","journal-title":"Dig. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3892\/etm.2014.1599","article-title":"Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer","volume":"7","author":"Cui","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Glehen, O., Passot, G., Villeneuve, L., Vaudoyer, D., Bin-Dorel, S., Boschetti, G., Piaton, E., and Garofalo, A. (2014). GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: A randomized and multicenter phase III study. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-183"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7244","DOI":"10.1245\/s10434-022-12383-6","article-title":"Don\u2019t Call It a Comeback-HIPEC for Gastric Cancer","volume":"29","author":"Badgwell","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jso.21068","article-title":"The intraoperative staging systems in the management of peritoneal surface malignancy","volume":"98","author":"Portilla","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jso.21072","article-title":"Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy","volume":"98","author":"Kusamura","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis","volume":"44","author":"Manzanedo","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomized, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","article-title":"Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal\/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer","volume":"24","author":"Yonemura","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1245\/s10434-017-6047-4","article-title":"Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma","volume":"24","author":"Badgwell","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","author":"Yonemura","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_47","first-page":"148420","article-title":"Effects of neoadjuvant intraperitoneal\/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer","volume":"2012","author":"Yonemura","year":"2012","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1245\/s10434-013-3443-2","article-title":"Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan","volume":"21","author":"Canbay","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.ejso.2019.03.011","article-title":"Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis","volume":"45","author":"Hao","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15330338211036310","DOI":"10.1177\/15330338211036310","article-title":"Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy with Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis: A Propensity Score Matched Analysis","volume":"20","author":"Zhang","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: Rationale and technique","volume":"2","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C","article-title":"Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery","volume":"79","author":"Fujimoto","year":"1997","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1515\/pp-2021-0152","article-title":"Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: A systematic review","volume":"7","author":"Noiret","year":"2022","journal-title":"Pleura Peritoneum"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1485","article-title":"The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastases (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial), abstract 13760","volume":"32","author":"Rau","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kusamura, S., Bhatt, A., Hubner, M., Villeneuve, L., Deraco, M., Bakrin, N., Van Der Speeten, K., and Glehen, O. (2023). The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology. Ann. Surg. Oncol.","DOI":"10.1245\/s10434-022-12990-3"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-012-2360-0","article-title":"Laparoscopic hyperthermic intraperitoneal chemotherapy: Indications, aims, and results: A systematic review of the literature","volume":"19","author":"Facchiano","year":"2012","journal-title":"Ann. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","article-title":"High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis","volume":"244","author":"Esquis","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.21037\/jgo-2020-22","article-title":"PIPAC may work but more data is needed","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:55:39Z","timestamp":1760122539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":60,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cancers15061777"],"URL":"https:\/\/doi.org\/10.3390\/cancers15061777","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}